Title : A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes.

Pub. Date : 2007 Mar

PMID : 17307426






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 High-sensitivity C-reactive protein levels decreased by an average of 68% in the rosiglitazone group (5.99 +/- 0.88 to 1.91 +/- 0.28 mg/L, P < .001), compared with a nonsignificant 4% reduction in hsCRP with metformin (5.69 +/- 0.83 to 5.46 +/- 0.92 mg/L; P = nonsignificant). Rosiglitazone C-reactive protein Homo sapiens